RSV vaccine and mAb snapshot

This slide provides a snapshot of the respiratory syncytial virus (RSV) vaccine and monoclonal antibody (mAb) technology landscape, in the effort to track the development of RSV vaccine and mAb candidates and provide a summary of the various vaccine approaches being worked on around the world.

This snapshot pairs with the RSV and mAb Trial Tracker, which provides publicly available information on clinical trials of RSV candidate vaccines and mAbs intended for prevention.

Corporate author(s): PATH

Publication date: January 2024

Available materials

    1. RSV vaccine and mAb snapshot (PDF) 169.6 KB PDF

      Hard copies are not available.
    2. RSV vaccine and mAb snapshot (PowerPoint) 429.6 KB PPTX